SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?


To: Andreas Helke who wrote (544)5/4/1998 4:38:00 PM
From: D.J.Smyth  Respond to of 2135
 
biologically, human testing relative to mice testing will most likely show little statistical difference relative to results. the idea that such a medicine will take five years for development was a conservative estimate. however, if it works (we know it works in mice and the concept is certainly appealing), it could realistically be on the market within two to three years. if endo works people dieing from cancer will request nothing less. just a personal opinion.



To: Andreas Helke who wrote (544)5/4/1998 4:43:00 PM
From: Tech Master  Respond to of 2135
 
Andreas-

I agree about your comments with regards to the potential promise of Endostatin. However, this is a classic example of a mania run up without regards to the risks associated with the stock and drug technologies.

I am concerned that the market perceives this company (and stock) as the cure for cancer. It is not. It is promising, but is there a reason for the stock to close up today 40+ dollars? No. The articles in the papers brought attention to the sector, but nothing really changed from Friday.

Rule One in investing: When presented with an enormous profit opportunity on a stock YOU TAKE THE PROFIT.

In several days the stock will be about 1/2 of where it is right now... should you hold here and watch 1/2 of your near term value disappear? NO! You lock in the profits tomorrow buy back your shares within a week for free!

Just my opinion,

Tech Master



To: Andreas Helke who wrote (544)5/4/1998 9:27:00 PM
From: jawd  Respond to of 2135
 
>>> If it turns out that Endostatin does not work in humans the investment will be a bust but that is the risk of early development stage biotechs with a very promising drug candidate.
<<<

Most humans are rats anyway, so it should work! :))))